Description
About Halaven: Halaven stands as a pioneering pharmaceutical solution crafted by Eisai Co., designed to combat advanced breast cancer in patients who have previously received at least two chemotherapeutic regimens. Eribulin, the active ingredient in Halaven, belongs to a class of drugs known as microtubule inhibitors. It works by inhibiting the growth of cancer cells, thereby impeding the progression of the disease.
Key Features:
- Advanced Treatment: Halaven represents an advanced treatment option for patients with metastatic breast cancer who have experienced disease progression after prior therapies.
- Eribulin 0.44mg/Ml Injection: Each milliliter of Halaven contains 0.44 milligrams of Eribulin, ensuring precise dosing and potent therapeutic effects.
- Microtubule Inhibition: Eribulin exerts its anticancer activity by disrupting microtubule dynamics, leading to cell cycle arrest and ultimately inducing cancer cell death.
- Quality Assurance: Manufactured by Eisai Co., Halaven adheres to rigorous quality standards, ensuring safety, purity, and efficacy in every dose.
- Clinically Validated: Halaven’s efficacy and safety profile have been clinically validated through extensive trials, establishing it as a trusted therapeutic option for oncologists and patients alike.
- Convenient Administration: Halaven is formulated for easy administration through intravenous injection, providing healthcare professionals with a convenient option for cancer treatment.
Indications: Halaven is indicated for the treatment of:
- Patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease.
Usage Directions: Halaven should be administered under the supervision of a qualified healthcare professional experienced in the use of anticancer agents. The recommended dosage and administration schedule may vary based on individual patient factors and disease characteristics. It is essential to follow the prescribing physician’s instructions closely and adhere to the prescribed treatment regimen.
Storage Information:
- Store Halaven vials in the original packaging at controlled room temperature (20°C to 25°C).
- Protect from light and moisture.
- Do not freeze.
- Keep out of reach of children and pets.
Caution:
- Halaven is contraindicated in patients with a known hypersensitivity to Eribulin or any of the excipients in the formulation.
- Serious adverse reactions, including neutropenia, neuropathy, and QT prolongation, have been associated with the use of Halaven. Close monitoring and appropriate supportive care are recommended during treatment.
Availability: Halaven (Eribulin 0.44mg/Ml Injection) is available by prescription only and can be obtained from authorized healthcare facilities and pharmacies.
Disclaimer: The information provided herein is for informational purposes only and should not be construed as medical advice or a substitute for professional medical consultation. Patients should consult their healthcare providers regarding diagnosis, treatment, and potential side effects associated with Halaven therapy.
Reviews
There are no reviews yet.